RT Journal Article
T1 Antibody-functionalized polymer nanoparticle leading to memory recovery in Alzheimer's disease-like transgenic mouse model
A1 Carradori, Dario
A1 Balducci, Claudia
A1 Re, Francesca
A1 Brambilla, Davide
A1 Le Droumaguet, Benjamin
A1 Flores, Orfeu
A1 Gaudin, Alice
A1 Mura, Simona
A1 Forloni, Gianluigi
A1 Ordóñez Gutiérrez, Lara
A1 Wandosell, Francisco
A1 Masserini, Massimo
A1 Couvreur, Patrick
A1 Nicolas, Julien
A1 Andrieux, Karine
AB Alzheimer's disease (AD) is a neurodegenerative disorder related, in part, to the accumulation of amyloid-β peptide (Aβ) and especially the Aβ peptide 1-42 (Aβ1-42). The aim of this study was to design nanocarriers able to: (i) interact with the Aβ1-42 in the blood and promote its elimination through the “sink effect” and (ii) correct the memory defect observed in AD-like transgenic mice. To do so, biodegradable, PEGylated nanoparticles were surface-functionalized with an antibody directed against Aβ1-42. Treatment of AD-like transgenic mice with anti-Aβ1-42-functionalized nanoparticles led to: (i) complete correction of the memory defect; (ii) significant reduction of the Aβ soluble peptide and its oligomer level in the brain and (iii) significant increase of the Aβ levels in plasma. This study represents the first example of Aβ1-42 monoclonal antibody-decorated nanoparticle-based therapy against AD leading to complete correction of the memory defect in an experimental model of AD.
PB Elsevier
SN 1549-9634
YR 2018
FD 2018-02
LK https://hdl.handle.net/20.500.14352/114186
UL https://hdl.handle.net/20.500.14352/114186
LA eng
NO Carradori, D., Balducci, C., Re, F., Brambilla, D., Le Droumaguet, B., Flores, O., Gaudin, A., Mura, S., Forloni, G., Ordoñez-Gutierrez, L., Wandosell, F., Masserini, M., Couvreur, P., Nicolas, J., & Andrieux, K. (2018a). Antibody-functionalized polymer nanoparticle leading to memory recovery in Alzheimer’s disease-like transgenic mouse model. Nanomedicine: Nanotechnology, Biology and Medicine, 14(2), 609-618. https://doi.org/10.1016/j.nano.2017.12.006
DS Docta Complutense
RD 18 abr 2025